Shirley Jane Peters

This inventor holds 8 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 6 EPO patents. Top assignees: Ucb Biopharma Sprl, Ucbbiopharma Srl, Ucb Pharma, S.a.. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shirley Jane Peters. Retrieved from https://idiyas.com/inventor/shirley-jane-peters

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 4)

% Patents Active = 87.5

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 11)

Average Co-Inventor Count = 2.8

ph-index = 3

Forward Citations = 28(Granted Patents)

Location History:

Berkshire, GB (2020)
Slough, GB (2014 - 2022)

Company Filing History:

Years Active: 2014-2024

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12091450 - Antibodies of the class IGG4 (2024-09-17),

2. 11352414 - Multimeric Fc proteins (2022-06-07),

3. 11059911 - Sequence symmetric modified IgG4 bispecific antibodies (2021-07-13),

4. 10562966 - Antibodies of the class IGG4 (2020-02-18),

5. 10221251 - Sequence symmetric modified IGG4 bispecific antibodies (2019-03-05),

6. 9902768 - Sequence asymmetric modified IgG4 bispecific antibodies (2018-02-27),

7. 9476081 - Method for producing protein (2016-10-25),

8. 8828719 - Method for producing protein (2014-09-09),

Title: The Innovative Contributions of Shirley Jane Peters

Introduction

Shirley Jane Peters is a notable inventor based in Slough, GB. She has made significant contributions to the field of biopharmaceuticals, holding a total of 8 patents. Her work primarily focuses on the development of antibodies and multimeric fusion proteins, which have important applications in treating immune disorders.

Latest Patents

One of her latest patents is titled "Antibodies of the class IGG4." This invention provides an antibody of the class IgG4 that includes at least one heavy chain with a C1 domain and a hinge region. In this antibody, the inter-chain cysteine at position 127, according to the Kabat numbering system, is substituted with another amino acid. Additionally, one or more amino acids in the upper hinge region are substituted with cysteine. Another significant patent is for "Multimeric Fc proteins," which relates to multimeric fusion proteins that bind to human Fc receptors. This invention also encompasses therapeutic compositions that include these proteins and their use in treating immune disorders.

Career Highlights

Shirley has worked with prominent companies in the biopharmaceutical sector, including UCB Biopharma Sprl and UCB Biopharma Srl. Her expertise and innovative spirit have allowed her to contribute to advancements in medical treatments and therapies.

Collaborations

Throughout her career, Shirley has collaborated with esteemed colleagues such as David Paul Humphreys and Paul Edward Stephens. These partnerships have further enhanced her research and development efforts in the field.

Conclusion

Shirley Jane Peters is a pioneering inventor whose work in biopharmaceuticals has led to significant advancements in the treatment of immune disorders. Her contributions, reflected in her patents, demonstrate her commitment to innovation and improving healthcare outcomes.

Profile summary based on public USPTO records.